{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:36:36Z","timestamp":1791272196398,"version":"4.1.0"},"reference-count":27,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Immunotherapies and targeted therapies are frequently associated with thyroid dysfunction, which is in contrast with the rare thyroid abnormalities induced by cytotoxic agents. Immunotherapy with NY-ESO-1, a tumor-associated antigen expressed by a number of malignancies, was reported to trigger hyperthyroidism or hypothyroidism in two HLA-A2 patients with ovarian cancer. We describe now a case of Graves' disease triggered by NY-ESO-1 in a HLA-A2\u2013negative woman.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient Findings:<\/jats:title>\n                    <jats:p>A 32-year-old woman with a synovial sarcoma received radiotherapy, chemotherapy, and finally NY-ESO-1 vaccine. The patient was found to have HLA A11\/A33(19), B13\/B56(22), Cw3\/\u2212. One month after the beginning of immunotherapy, thyroid dysfunction was clinically suspected and Graves' disease was biochemically confirmed. Fearful of the antithyroid drugs' side effects, the patient was treated with a beta-blocker (propranolol, 80\u201320\u2009mg\/day). As hyperthyroidism progressively worsened, the patient underwent total thyroidectomy. We hypothesized that NY-ESO-1 shared partial homology with thyroid autoantigens (the so-called molecular mimicry mechanism) and that at least one pair of homologous sequences contained amino acid sequence binding motifs to a restricted number of HLA molecules. We used BLAST software to search amino acid sequence homologies between NY-ESO-1 and thyroid autoantigens (thyrotropin receptor [TSH-R], thyroperoxidase, and thyroglobulin), and the HLA ligand\/motif database to look for HLA\/T-cell receptor binding motifs in the regions of NY-ESO-1 and thyroid autoantigens that were homologous. We found 15 epitopic regions of NY-ESO-1 homologous to 15 regions of thyroid autoantigens, some of which epitopic: 5 of TSH-R, 8 of thyroglobulin, and 2 of thyroperoxidase. These homologous sequences contain binding motifs belonging to several HLA class I antigens, including HLA A2 and the patient's A11 and A33.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary:<\/jats:title>\n                    <jats:p>Genetically predisposed patients who receive NY-ESO-1 vaccination are at risk to develop thyroid dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Considering the increasing use of NY-ESO-1, thyroid dysfunctions induced by NY-ESO-1 are expected to increase in cancer patients over the next years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/thy.2013.0170","type":"journal-article","created":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T15:14:03Z","timestamp":1366125243000},"page":"390-394","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":23,"title":["Autoimmune Thyroid Disease Elicited by NY-ESO-1 Vaccination"],"prefix":"10.1177","volume":"24","author":[{"given":"Roberto","family":"Vita","sequence":"first","affiliation":[{"name":"University of Messina","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Guarneri","sequence":"additional","affiliation":[{"name":"University of Messina","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravin","family":"Agah","sequence":"additional","affiliation":[{"name":"Palo Alto Medical Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Benvenga","sequence":"additional","affiliation":[{"name":"University of Messina","place":["Italy"]},{"name":"University of Messina","place":["Italy"]},{"name":"A.O.U. Policlinico G. Martino","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2014,2,1]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr373"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2002.18811.x"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0733-4"},{"key":"e_1_3_2_5_2","first-page":"16","article-title":"Cancer-testis antigens: targets for cancer immunotherapy","volume":"5","author":"Chen YT","year":"1999","unstructured":"Chen YT, , Old LJ. 1999. Cancer-testis antigens: targets for cancer immunotherapy. Cancer J Sci Am, 5:16\u201317.","journal-title":"Cancer J Sci Am"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2010.0149"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4619"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Altschul SF Madden TL Sch\u00e4ffer AA Zhang J Zhang Z Miller W Lipman DJ. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25:3389\u20133402. (Software freely available at http:\/\/blast.ncbi.nlm.nih.gov\/Blast.cgi. Accessed January15 2013).","DOI":"10.1093\/nar\/25.17.3389"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2003.610102.x"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.0234"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.K10E-130"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.6-1-34"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802670"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2010.09.007"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904083401404"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2537"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-249458"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.05.044"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.2.265"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.061507398"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e3282ef1c48"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197412262912607"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0198-8859(92)90101-R"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1994.tb01090.x"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.3109\/08820139609059294"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00920242"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2007.11.010"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1989.tb01734.x"}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/thy.2013.0170","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2013.0170","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2013.0170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:55:22Z","timestamp":1777701322000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/thy.2013.0170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1089\/thy.2013.0170"],"URL":"https:\/\/doi.org\/10.1089\/thy.2013.0170","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}